Latest research on TNF-R2

Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids

TNF-R2 interactions

Biologic agents were mainly in decreasing order of frequency: etanercept (Enbrel), adalimumab (Humira), abatacept (Orencia), rituximab (MabThera), and tocilizumab (Actemra). [source, 2016]
Plasma samples were assessed (as indicated) for levels of Ang1, Ang2, Angiopoietin-Like 3 (AngptL3), Vascular Endothelial Growth Factor (VEGF-A), Factor D, Monocyte Chemoattractant Protein-1 (MCP-1), Interleukin-1 Beta (IL1B), Soluble fms-like TYROSINE kinase 1 (sFlt-1), soluble Tumor necrosis factor receptor 2 (sTNFR2), Placental Growth Factor (PGF), Macrophage Inflammatory Protein-1 Beta (MIP-1β), Leptin, Interleukin-18 Binding Protein (IL-18BP), soluble Intercellular Adhesion Molecule-1 (sICAM-1), soluble Endoglin (sEndoglin), C-reactive protein (CRP), Chitinase-3-Like Protein-1 (CHI3L1), and complement component C5a (C5a) using commercially available enzyme linked immunosorbent assay (ELISA) kits (Duosets, R&D Systems, Minneapolis, MN). [source, 2015]
Fatigued breast cancer survivors had higher levels of proinflammatory activity including interleukin-1 receptor antagonist (IL-1ra), soluble Tumor necrosis factor receptor type II (sTNF-RII), and neopterin (a marker of macrophage activation), than breast cancer survivors who were not fatigued [10]. [source, 2015]
The eligible drug list currently comprises adalimumab (Humira), etanercept (Enbrel) and certolizumab pegol (Cimzia). [source, 2015]
Biologic disease-modifying antirheumatic drugs (bDMARDs), also known as biologics, cover TNF inhibitors (TNFi) (adalimumab (ADA) (Humira, AbbVie Ltd.), certolizumab pegol (CER) (Cimzia, UCB Pharma SA), etanercept (ETN) (Enbrel, Pfizer Ltd.), golimumab (GOL) (Simponi, Janssen Biologics B.V), infliximab (IFX) (Remicade, Janssen Biologics B.V.)) and agents based on other mechanisms of action (abatacept (ABT) (Orencia, Bristol-Myers Squibb Pharma EEIG), anakinra (ANA) (Kineret, Biovitrum AB), rituximab (RTX) (MabThera, Roche Registration Ltd) and tocilizumab (TOC) (RoActemra, Roche Registration Ltd. [source, 2015]
Mice were treated with PBS, bortezomib (Millennium Pharmaceuticals, Cambridge, MA) at the doses of 0.75 or 0.15 mg/kg (Velcade (H) and (L) groups, resp.), or etanercept (Enbrel, Wyeth Pharmaceuticals, Hampshire, UK) at the dose of 5 mg/kg in 0.1 mL by i.p. injection twice a week starting on the day of EAU induction. [source, 2015]
Additionally, for all participants except four controls, blood samples were collected on the same day as the MRI exam (with the exception of four participants with bipolar disorder whose blood was collected during a visit 10 to 16 months prior to the exam) to measure the levels of 14 peripheral inflammatory markers (C-reactive protein, interleukin (IL)-1β, IL-1ra, IL-4, IL-6, IL-10, IL-17, IL-18, IL-18BP, interferon γ, tumor necrosis factor (TNF)-α, TNF-R1, TNF-R2, and monocyte chemotactic protein 1). [source, 2015]
The first available molecule targeting TNF-alpha was a chimeric IgG monoclonal antibody infliximab (Remicade, Schering-Plough Pharma Inc.); later etanercept (Enbrel, White Pharmaceuticals Inc.), a p75 TNF-alpha receptor fusion protein, was developed. [source, 2015]
Moreover, we show that the administration of bisphosphonate (Aclasta) or mOPG to Mushi Tg mice, but not Etanercept (Enbrel, a TNFα-neutralizing antibody), prevented the apparition of bone lesions. [source, 2015]
Two medications known to block the inflammatory molecule tumor necrosis factor-α are etanercept (Enbrel, Amgen, Inc., Thousand Oaks, CA and Wyeth, Madison, NJ) and infliximab (Remicade, Centocor, Horsham, PA). [source, 2015]